Precision Other Stockholder Equity vs Cash And Short Term Investments Analysis
DTIL Stock | USD 7.24 0.02 0.28% |
Precision BioSciences financial indicator trend analysis is much more than just breaking down Precision BioSciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Precision BioSciences is a good investment. Please check the relationship between Precision BioSciences Other Stockholder Equity and its Cash And Short Term Investments accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.
Other Stockholder Equity vs Cash And Short Term Investments
Other Stockholder Equity vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Precision BioSciences Other Stockholder Equity account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong relationship.
The correlation between Precision BioSciences' Other Stockholder Equity and Cash And Short Term Investments is 0.74. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Precision BioSciences, assuming nothing else is changed. The correlation between historical values of Precision BioSciences' Other Stockholder Equity and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Precision BioSciences are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Other Stockholder Equity i.e., Precision BioSciences' Other Stockholder Equity and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.74 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Other Stockholder Equity
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Precision BioSciences balance sheet. This account contains Precision BioSciences investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Precision BioSciences fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Precision BioSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Precision BioSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.At this time, Precision BioSciences' Sales General And Administrative To Revenue is quite stable compared to the past year. Enterprise Value Over EBITDA is expected to rise to 1.42 this year, although the value of Selling General Administrative will most likely fall to about 29 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 115.5M | 16.1M | 40.5M | 33.4M | Total Revenue | 115.5M | 25.1M | 48.7M | 35.8M |
Precision BioSciences fundamental ratios Correlations
Click cells to compare fundamentals
Precision BioSciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Precision BioSciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 235.2M | 150.2M | 211.5M | 238.2M | 159.8M | 179.4M | |
Other Current Liab | 1.6M | 7.9M | 9.9M | 11.1M | 11.4M | 6.7M | |
Total Current Liabilities | 26.9M | 42.8M | 36.0M | 59.7M | 50.0M | 34.0M | |
Total Stockholder Equity | 138.3M | 44.4M | 91.2M | 60.4M | 18.9M | 17.9M | |
Other Liab | 70.0M | 54.3M | 77.1M | 93.1M | 83.8M | 64.4M | |
Net Tangible Assets | 136.9M | 43.1M | 89.1M | 59.1M | 67.9M | 52.7M | |
Retained Earnings | (177.1M) | (286.1M) | (316.7M) | (428.3M) | (489.6M) | (465.1M) | |
Accounts Payable | 2.0M | 792K | 1.1M | 653K | 3.0M | 1.8M | |
Cash | 180.9M | 89.8M | 143.7M | 189.6M | 116.7M | 134.8M | |
Other Assets | 558K | 8.1M | 11.5M | 9.8M | 1.0 | 0.95 | |
Cash And Short Term Investments | 180.9M | 89.8M | 143.7M | 189.6M | 116.7M | 134.8M | |
Net Receivables | 965K | 10M | 488K | 720K | 12.8M | 13.4M | |
Common Stock Shares Outstanding | 1.4M | 1.7M | 2.0M | 2.9M | 3.8M | 3.1M | |
Capital Surpluse | 316.3M | 331.5M | 408.8M | 489.7M | 563.2M | 591.3M | |
Total Liab | 96.9M | 105.7M | 120.3M | 177.7M | 140.9M | 129.6M | |
Total Current Assets | 193.7M | 105.6M | 161.8M | 199.1M | 136.4M | 147.2M | |
Intangible Assets | 1.4M | 1.4M | 2.0M | 1.3M | 400K | 380K | |
Property Plant Equipment | 39.6M | 41.5M | 25.2M | 20.2M | 23.2M | 25.0M | |
Property Plant And Equipment Net | 39.6M | 41.5M | 29.3M | 23.2M | 14.6M | 27.9M | |
Current Deferred Revenue | 16.5M | 30.2M | 21.2M | 46.2M | 12.0M | 22.1M | |
Net Debt | (180.9M) | (79.3M) | (134.6M) | (162.5M) | (85.4M) | (89.7M) | |
Non Current Assets Total | 41.6M | 44.6M | 49.7M | 39.1M | 23.4M | 36.1M | |
Non Currrent Assets Other | 558K | 1.7M | 4.6M | 9.8M | 225.0K | 213.7K | |
Liabilities And Stockholders Equity | 235.2M | 150.2M | 211.5M | 238.2M | 159.8M | 189.5M | |
Non Current Liabilities Total | 70.0M | 62.9M | 84.4M | 118.1M | 90.9M | 94.4M | |
Other Current Assets | 2.3M | 5.8M | 17.6M | 8.8M | 6.9M | 8.5M | |
Other Stockholder Equity | 315.4M | 330.5M | 407.8M | 488.7M | 508.5M | 345.3M | |
Net Invested Capital | 138.3M | 44.4M | 93.6M | 82.7M | 41.3M | 65.0M | |
Property Plant And Equipment Gross | 39.6M | 41.5M | 53.2M | 54.3M | 40.1M | 40.5M | |
Net Working Capital | 166.7M | 62.7M | 125.8M | 139.4M | 86.4M | 115.9M | |
Short Term Debt | 6.8M | 3.9M | 3.6M | 1.7M | 23.5M | 24.7M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.4 | Revenue Per Share 12.872 | Quarterly Revenue Growth (0.96) | Return On Assets (0.06) | Return On Equity 0.2444 |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.